pharmaphorum

AUGUST 18, 2022

bluebird bio’s Zynteglo has become the first cell-based gene therapy to be approved in the US, getting the nod from the FDA as a treatment for patients with beta thalassaemia who require regular blood transfusions. An FDA advisory committee recommended approval of Zynteglo on the strength of that data in June.

52

52

pharmaphorum

OCTOBER 4, 2022

In this article, Ben Hargreaves takes a look at the renewed effort to tackle deaths from cancer in the US through the Cancer Moonshot. Central to the initiative is the aim to gather data from willing participants that can provide greater insights into cancer development and treatment over time. Building a bank.

Documentation 87

Documentation HIPAA Data Entry 87

pharmaphorum

AUGUST 25, 2022

Tecvayli (teclistamab) has been approved by the European Commission for adults with the blood cancer whose disease has progressed have after at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, said J&J.

Immunity 89

Immunity Immunization 89

European Pharmaceutical Review

DECEMBER 27, 2023

1 Following in vitro production from T cells collected from a patient’s leukapheresis procedure, the CAR T cells are infused back into the patient’s blood, where they proliferate and expand. This is in addition to its considerable price tag. Chimeric antigen receptor (CAR) T cells are the first example of a “living drug”.

Adverse Reactions 82

Adverse Reactions Immunity Immunization Medical Schools 82

pharmaphorum

JANUARY 5, 2021

The FDA’s breakthrough status is for tiragolumab plus Tecentriq is the first for a TIGIT drug, and covers the first-line treatment of patients with advanced-stage non-small cell lung cancer (NSCLC) that expresses high levels of PD-L1. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Chemotherapy 52

Chemotherapy Immunity Immunization Labelling 52

pharmaphorum

JANUARY 11, 2021

While bluebird has conducted pioneering work in gene therapy for blood disorders and in cancer cell therapy, products have been delayed by issues with filing data for the FDA. million price tag. Leschly will also take the role of executive chair at bluebird, according to a company statement.

58

58

pharmaphorum

DECEMBER 12, 2022

. “This is exciting news because existing treatments fail to improve platelet counts for as many as 30% of adults with chronic ITP,” commented said Catherine Broome of Georgetown Lombardi Cancer Centre in Washington DC, the trial’s lead investigator.

Immunity 52

Immunity Immunization Labelling 52

pharmaphorum

NOVEMBER 19, 2020

But it has been a source of controversy – it works by attacking the rogue blood vessels that build up in the retina that are the root cause of wet AMD, something that Roche’s Avastin (bevacizumab) cancer drug can do in an off-label use at a fraction of the price.

Biosimilars 62

Biosimilars Labelling 62

pharmaphorum

JULY 25, 2022

The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer.

52

52

RX Note

FEBRUARY 9, 2024

Introduction A colleague once stumped me with a question: "What is the medical term for coughing out blood?". Apnoea 呼吸暂停 - A temporary pause in breathing during sleep that can be very brief or can last so long that the amount of oxygen in the blood drops dangerously low. Benign 良性 - Not cancerous. Arthralgia 关节痛 - Joint pain.

Immunity 40

Immunity Immunization Diabetes Communication 40

Fuld & Company Blog

MARCH 27, 2023

The background of semaglutide Nearly 20 years ago the first glucagon-like peptide 1 (GLP-1), a class of Type 2 diabetes drug that improves blood sugar, was launched, creating what is today a market worth nearly $30B. With trials showing potential weight loss of 10% to 15% , for many, the price tag of $1,500 per month is well worth it.

Diabetes 52

Diabetes Online Pharmacies Packaging Pharmaceutical Companies 52

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. With blood cancers, you inject the product, and the cells are there, and the target is there. We also have the challenge of delivery.

Immunity 59

Immunity Immunization 59

pharmaphorum

FEBRUARY 26, 2021

The company has also faced claims that it did not adequately communicate the risks of its opioid painkillers in its marketing, contributing to the US’ ‘opioid epidemic’, and that its talc products could contain small amounts of asbestos and lead to cancer. But ultimately these dips are likely to only be blips on the radar for J&J.

Vaccines 108

Vaccines Biosimilars Labelling Diabetes 108

epicur

MAY 16, 2024

In ophthalmology, you get to do: Internal Medicine: Systemic workups for diseases that you can detect in the eye, like high blood pressure, some types of cancer, and even detect hormonal imbalances in the eye. Oncology: Eyelid and orbital tumors, tumors inside the eye. It just blossomed from there!

Compounding 52

Compounding Hospitals 52

Pharma Marketing Network

JUNE 8, 2020

I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication.

Health and Personal Care Stores 40

Health and Personal Care Stores Hospitals Mayo Clinic Specialty Pharmacies 40